Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA

RNAi technology is taking strong position among the key therapeutic modalities, with dozens of siRNA-based programs entering and successfully progressing through clinical stages of drug development. To further explore potentials of RNAi technology as therapeutics, we engineered and tested VEGFR2 siR...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaoxia, Wang, Wei, Samarsky, Dmitry, Liu, Li, Xu, Qian, Zhang, Wenqing, Zhu, Guangzu, Wu, Ping, Zuo, Xialin, Deng, Houliang, Zhang, Jingjing, Wu, Zhuomin, Chen, Xiaohui, Zhao, Lingfeng, Qiu, Zhiyong, Zhang, Zhongyi, Zeng, Qiyi, Yang, Wei, Zhang, Biliang, Ji, Aimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
RNA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191406/
https://www.ncbi.nlm.nih.gov/pubmed/25223783
http://dx.doi.org/10.1093/nar/gku831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191406/
https://www.ncbi.nlm.nih.gov/pubmed/25223783
http://dx.doi.org/10.1093/nar/gku831

Ejemplares similares